WallStSmart

GE HealthCare Technologies Inc. (GEHC)vsStandard Biotools Inc (LAB)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 24222% more annual revenue ($20.98B vs $86.25M). LAB leads profitability with a 90.7% profit margin vs 9.1%. GEHC earns a higher WallStSmart Score of 57/100 (C).

GEHC

Buy

57

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 5.7Quality: 4.5
Piotroski: 2/9Altman Z: 1.34

LAB

Hold

45

out of 100

Grade: D+

Growth: 3.3Profit: 4.0Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: -1.01

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GEHC2 strengths · Avg: 8.0/10
P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

LAB3 strengths · Avg: 10.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Profit MarginProfitability
90.7%10/10

Keeps 91 of every $100 in revenue as profit

Debt/EquityHealth
0.0510/10

Conservative balance sheet, low leverage

Areas to Watch

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.834/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-30.9%2/10

Earnings declined 30.9%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

LAB4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
4.6%4/10

4.6% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$324.80M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-16.8%2/10

ROE of -16.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : GEHC

The strongest argument for GEHC centers on P/E Ratio, Price/Book.

Bull Case : LAB

The strongest argument for LAB centers on Price/Book, Profit Margin, Debt/Equity. Profitability is solid with margins at 90.7% and operating margin at -44.5%.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Bear Case : LAB

The primary concerns for LAB are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

LAB carries more volatility with a beta of 1.38 — expect wider price swings.

GEHC is growing revenue faster at 7.4% — sustainability is the question.

GEHC generates stronger free cash flow (112M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

GEHC scores higher overall (57/100 vs 45/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Standard Biotools Inc

HEALTHCARE · MEDICAL DEVICES · USA

Standard Biotools Inc. (LAB) is a pioneering biotechnology company dedicated to enhancing genomic analysis and biological research through cutting-edge tools and technologies. The firm's focus on developing high-performance products for laboratories in genomics and proteomics is aimed at improving research precision and operational efficiency. Utilizing proprietary platforms, Standard Biotools accelerates scientific discoveries, reinforcing its position as a leader in the dynamic biotechnology landscape. With a commitment to meeting the growing demand for innovative analytical solutions, LAB is strategically positioned to facilitate significant advancements within the life sciences sector.

Want to dig deeper into these stocks?